What was the value per share used for the TBPH tax-withholding on August 20, 2026?

The Form 4 reports a value of $16.95 per Ordinary Share for the 8,112 shares withheld to satisfy tax obligations arising from the vesting of restricted stock units.

Theravance Biopharma (TBPH) CFO now holds 336,841 shares

Q: Was the August 20, 2026 TBPH insider transaction an open market sale?

No. The filing states the share withholding transaction was with the issuer and did not involve an open market transaction. Shares were withheld solely to satisfy tax obligations from vesting restricted stock units.

Q: How many TBPH shares does Aziz Sawaf hold after this Form 4 transaction?

After the tax-withholding event, Aziz Sawaf directly holds 336,841 Ordinary Shares of Theravance Biopharma, Inc. as reported in the Form 4 filing.

Q: Was the TBPH Form 4 transaction under a Rule 10b5-1 trading plan?

No. The Rule 10b5-1 checkbox is not affirmed in the filing (aff_10b5_one is false), and the footnote describes the event as shares withheld to satisfy tax obligations from RSU vesting.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Theravance Biopharma, Inc. (TBPH) reported that its SVP & Chief Financial Officer, Aziz Sawaf, had 8,112 Ordinary Shares withheld on 2026-08-20 to satisfy tax obligations arising from the vesting of previously granted restricted stock units. The shares were withheld by the issuer and did not involve an open market transaction. Following this tax-withholding event, Sawaf directly holds 336,841 Ordinary Shares.

Insights

Analyzing...

Insider Trade Summary

Net Seller: 8,112 shares

Net Sell 1 txn

Insider Sawaf Aziz

Role SVP & CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares ^F1	8,112	$16.95	$137K

Holdings After Transaction: Ordinary Shares — 336,841 shares (Direct)

Footnotes (1)

F1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

Key Figures

Shares withheld for tax obligations: 8,112 Ordinary Shares Per-share value for withholding: $16.95 per share Shares held after transaction: 336,841 Ordinary Shares +1 more

4 metrics

Shares withheld for tax obligations 8,112 Ordinary Shares Withheld on 2026-08-20 to satisfy tax obligations from RSU vesting

Per-share value for withholding $16.95 per share Applied to 8,112 Ordinary Shares withheld on 2026-08-20

Shares held after transaction 336,841 Ordinary Shares Direct holdings of Aziz Sawaf following the 2026-08-20 withholding

Number of Form 4 transactions reported 1 transaction Single tax-withholding disposition on 2026-08-20

Key Terms

restricted stock units, tax obligations, open market transaction

3 terms

restricted stock units financial

"arising out of the vesting of previously granted restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax obligations financial

"Shares withheld to satisfy tax obligations arising out of the vesting"

open market transaction financial

"did not involve an open market transaction"

An open market transaction is a buy or sell of publicly traded securities executed on an exchange or other public trading venue where many buyers and sellers can participate. It matters to investors because these trades change the visible supply and demand for a stock—like shoppers moving prices in a busy marketplace—affecting share price, liquidity (how easily you can trade), and sometimes the balance of ownership.

FAQ

What insider transaction did TBPH report for Aziz Sawaf on August 20, 2026?

Theravance Biopharma (TBPH) reported that SVP & Chief Financial Officer Aziz Sawaf had 8,112 Ordinary Shares withheld on 2026-08-20 to cover tax obligations from the vesting of restricted stock units in a non-open-market transaction with the issuer.

Was the August 20, 2026 TBPH insider transaction an open market sale?

No. The filing states the share withholding transaction was with the issuer and did not involve an open market transaction. Shares were withheld solely to satisfy tax obligations from vesting restricted stock units.

How many TBPH shares does Aziz Sawaf hold after this Form 4 transaction?

After the tax-withholding event, Aziz Sawaf directly holds 336,841 Ordinary Shares of Theravance Biopharma, Inc. as reported in the Form 4 filing.

Was the TBPH Form 4 transaction under a Rule 10b5-1 trading plan?

No. The Rule 10b5-1 checkbox is not affirmed in the filing (aff_10b5_one is false), and the footnote describes the event as shares withheld to satisfy tax obligations from RSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/24/2026 - 06:08 PM Accepted by SEC EDGAR 08/24/2026 - 06:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sawaf Aziz

(Last)

(First)

(Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP & CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	08/20/2026		F		8,112⁽¹⁾	D	$16.95	336,841	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A Grimaud, Attorney-in-Fact	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR